Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Expenses: 2009-2025

Historic Operating Expenses for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Sep 2025 value amounting to $401.2 million.

  • Madrigal Pharmaceuticals' Operating Expenses rose 124.81% to $401.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 67.74%. This contributed to the annual value of $678.0 million for FY2024, which is 78.19% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Operating Expenses of $401.2 million as of Q3 2025, which was up 54.32% from $260.0 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Operating Expenses' 5-year high stood at $401.2 million during Q3 2025, with a 5-year trough of $53.0 million in Q1 2021.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Operating Expenses value was $170.3 million (recorded in 2024), while the average stood at $176.0 million.
  • Data for Madrigal Pharmaceuticals' Operating Expenses shows a peak YoY skyrocketed of 124.81% (in 2025) over the last 5 years.
  • Over the past 5 years, Madrigal Pharmaceuticals' Operating Expenses (Quarterly) stood at $64.6 million in 2021, then spiked by 32.04% to $85.3 million in 2022, then surged by 37.37% to $117.2 million in 2023, then surged by 45.35% to $170.3 million in 2024, then spiked by 124.81% to $401.2 million in 2025.
  • Its last three reported values are $401.2 million in Q3 2025, $260.0 million for Q2 2025, and $216.6 million during Q1 2025.